Odimma Therapeutics, a biotechnology company specialized in personalized cancer immunotherapy announces a seed fundraising of €2 million in order to secure the preparation on its First-in-Man clinical
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma's neoantigen program Touchlight, a biotechnology company pioneering enzymatic DNA production
PARIS , May 17, 2022 /PRNewswire/ ABL Europe (ABL), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine
ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY laragione.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laragione.eu Daily Mail and Mail on Sunday newspapers.